<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5617481</article-id><article-id pub-id-type="pmid">28977921</article-id><article-id pub-id-type="publisher-id">18779</article-id><article-id pub-id-type="doi">10.18632/oncotarget.18779</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Docking of <italic>CDK1</italic> with antibiotic drugs revealed novel therapeutic value in breast ductal cancer <italic>in situ</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Zhong-Hai</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Jia</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shang</surname><given-names>An-Quan</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yu-Jie</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="author-notes" rid="FN2">**</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="author-notes" rid="FN2">**</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Li-Qing</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wei-Wei</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Man</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><aff id="A1"><sup>1</sup> Department of Senior Cadres&#8217; Healthcare, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu, China</aff><aff id="A2"><sup>2</sup> Department of Dermatology, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi 214002, Jiangsu, China</aff><aff id="A3"><sup>3</sup> Department of Laboratory Medicine, Tongji Hospital of Tongji University, Shanghai 200092, Shanghai, China</aff><aff id="A4"><sup>4</sup> The Sixth People&#8217;s Hospital of Yancheng City, Yancheng 224005, Jiangsu, China</aff><aff id="A5"><sup>5</sup> Clinical Medicine School, Ningxia Medical University, Yinchuan 750004, Ningxia, China</aff><aff id="A6"><sup>6</sup> Department of Laboratory Medicine, The first Hospital of Ningbo City, Ningbo 315010, Zhejiang, China</aff><aff id="A7"><sup>7</sup> Department of Pathology, The First People&#8217;s Hospital of Yancheng City and The Sixth People&#8217;s Hospital of Yancheng City, Yancheng 224001, Jiangsu, China</aff><aff id="A8"><sup>8</sup> Department of Laboratory Medicine, TCM Hospital of Yancheng City Affiliated to Nanjing University of Chinese Medicine, Yancheng 224001, Jiangsu, China</aff></contrib-group><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic> Wei-Wei Wang, </italic><email>lydia_wangweiwei@sina.com</email></corresp><corresp id="cor2"><italic>Li-Qing Hu, </italic><email>13605887858@163.com</email></corresp><corresp id="cor3"><italic>Man Yang, </italic><email>x_yangman@163.com</email></corresp><fn id="FN1" fn-type="other"><label>*</label><p>Zhong-Hai Ding, Jia Qi and An-Quan Shang are the first authors</p></fn><fn id="FN2" fn-type="other"><label>**</label><p>Yu-Jie Zhang and Jun Wei are the second authors</p></fn></author-notes><pub-date pub-type="collection"><day>5</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2017</year></pub-date><volume>8</volume><issue>37</issue><fpage>61998</fpage><lpage>62010</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#169; 2017 Ding et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>The aim of our research is to identify potential genes associated with Ductal carcinoma <italic>in situ</italic> (DCIS) through microarrays. The microarray dataset GS54665 were downloaded from the GEO(Gene Expression Omnibus) database. Dysregulated genes were screened and their associations with DCIS was analyzed by comprehensive bioinformatics tools. A total of 649 differential expression genes were identified between normal and DCIS samples, including 224 up-regulated genes and 425 down-regulated genes. Biological process annotation and pathway enrichment analysis identified several DCIS-related signaling pathways. Finally, PPI network was constructed with String website in order to get the hub codes involved in Ductal carcinoma in situ. We thus concluded that Five genes: <italic>CDK1</italic>, <italic>CCNB2</italic>, <italic>MAD2L1</italic>, <italic>PPARG</italic>, <italic>ACACB</italic> were finally identified to participate in the regulation and serve as potential diagnosis signatures in in Ductal carcinoma in situ. Finally, complmentarity between <italic>CDK1</italic> and three drugs, Aminophenazone, Pomalidomide and the Rosoxacin, implies novel pharmacological value of those drugs in breast cancer.</p></abstract><kwd-group><kwd>ductal cancer <italic>in situ</italic></kwd><kwd>GEO</kwd><kwd>molecular signature</kwd><kwd>microarray</kwd><kwd>protein docking</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Ductal carcinoma in situ (DCIS) comprises a heterogeneous group of neoplastic lesions confined to the breast ducts [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>], which subject to clonal proliferation of epithelial malignant cells yet does not exhibit stromal invasion into adjacent breast stroma under microscopic examination. The increased prevelance of mammographic screening has tremendously changed the situation where DCIS had been underdiagnosed, and the past two decades witnessed the dramatic increase of detection rate. The 10-year cancer-specific survival of DCIS reached over 95%, indicating that early diagnosis would exert substantial influence on prognosis [<xref rid="R3" ref-type="bibr">3</xref>]. However, the heterogeneity of DCIS warrants comprehensive investigations into the molecular mechanisms to enlighten management of this disease [<xref rid="R4" ref-type="bibr">4</xref>].</p><p>Traditionally, the diagnosis of DCIS relied on mammography and clinic pathologic findings [<xref rid="R5" ref-type="bibr">5</xref>]. However, the accuracy suffered from high false positive rate and high false negative rate, resulting in under- or over-treatment of DCIS [<xref rid="R6" ref-type="bibr">6</xref>]. Therefore, characterization of molecular signatures holds the promise for improving diagnosis of DCIS. Multiple lines of evidence demonstrated that diagnosis, prognosis and therapy prediction gain remarkable improvement from molecular signature [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>], particularlyin identifying risk factors and early phase of carcinogenesis. Another compelling advantage of molecular signature resides in its non-invasive operation and relatively low cost, rendering it a promising method for seeking predictive and therapeutic biomarkers.</p><p>Microarray has been employed in characterizing themolecular mechanism of DCIS [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Several expression profiling researches of DCIS have been released, most of which were designed to identify key candidate genes implicated in the progression of DCIS to invasive ductal breast cancer (IDC) [<xref rid="R13" ref-type="bibr">13</xref>]. In this research, we collected 14 microarray data from microarray dataset: normal ductal cells from 5 patients; 9 surgical specimens with DCIS and proceeded several of bioinformatics analysis to recognize the molecular mechanism of DCIS. Gene with expression different between normal cells and cancer cells were identified. <italic>MAD2L1</italic>, <italic>CDK1</italic> and <italic>ACACB</italic> exhibit significantly distinctive expression patterns and may be highly involved in cacer related pathways of breast cancer, DCIS. Furthermore, docking analysis revealed that CDK1, a potential target of DCIS, has active site complementary with three antibiotic drugs, Pomalidomide and the Rosoxacin, indicating novel pharmacological utility of these drugs.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Analysis of DEGs</title><p>The expression profile were preprocessed and then analyzed by Affy package in R language. Total genes were screened. Cassette figures after data standardization was shown in Figure <xref ref-type="fig" rid="F1">1A</xref>. The alignment of black dots on the same line indicates good standardization.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Data process</title><p><bold>(A)</bold> data distribution after normalization; <bold>(B)</bold> Hierarchical cluster dendrogram of DEGs; <bold>(C)</bold> The DEGs in breast cancer in situ compared with those in normal samples</p></caption><graphic xlink:href="oncotarget-08-61998-g001"/></fig><p>Hierarchy cluster analysis demonstarted that the 9 breast cancer in situ samples and the 5 normal samples showed different distribution (Figure <xref ref-type="fig" rid="F1">1B</xref>). The result revealed that grouping was reasonable and the data can be directly applied to further analysis. A total of 649 DEGs were identified in normal ductal cells obtain from DCIS patients. There are 224 up-regulated genes and 425 down-regulated genes (Figure <xref ref-type="fig" rid="F1">1C</xref>). The top ten up-regulated genes (with the highest log-transformed fold change) were <italic>CEACAM6</italic>, <italic>S100P</italic>, <italic>RRM2</italic>, <italic>COL10A1</italic>, <italic>KMO</italic>, <italic>TFAP2B</italic>, <italic>SDC1</italic>, <italic>COMP</italic>, <italic>KIAA0101</italic> and <italic>GJB2</italic>. The top ten down-regulated genes (with the smallest log-transformed fold change) were <italic>CIDEC</italic>, <italic>PCOLCE2</italic>, <italic>HSPB7</italic>, <italic>ACVR1C</italic>, <italic>PLIN4</italic>, <italic>TUSC5</italic>, <italic>GPD1</italic>, <italic>TIMP4</italic>, <italic>LEP</italic> and <italic>CIDEA</italic> (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>The top 10 most up and downregulated genes</title></caption></table-wrap></sec><sec id="s2_2"><title>Function and pathway enrichment analysis</title><p>A total of 224 up-regulated genes and 425 down-regulated genes were uploaded to DAVID for GO enrichment (p &lt; = 0.05 as significant). Figure <xref ref-type="fig" rid="F2">2A</xref> and <xref ref-type="fig" rid="F2">2B</xref> showed the top enriched GO terms of up- and down-regulated genes separately. The up-regulated genes were mainly enriched in cell cycle phase, M phase, mitosis, nuclear division, mitotic cell cycle, M phase of mitotic cell cycle, organelle fission, cell division, cell cycle process and cell cycle (Table <xref ref-type="table" rid="T2">2</xref>), whereas the down-regulated genes were over-represented in response to endogenous stimulus, response to hormone stimulus, regulation of lipid metabolic process, plasma membrane part, plasma membrane, response to peptide hormone stimulus, response to organic substance, response to insulin stimulus, lipid particle and cell fraction, etc. (Table <xref ref-type="table" rid="T3">3</xref>). The KEGG pathways of up- and downregulated genes were summarized in Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>. The upregulated genes were mainly enriched in Cell cycle, Oocyte meiosis, Progesterone-mediated oocyte maturation, p53 signaling pathway and Systemic lupus erythematosus (Table <xref ref-type="table" rid="T4">4</xref>). Down-regulated genes were related to Glycerolipid metabolism, PPAR signaling pathway, Fatty acid metabolism, Pyruvate metabolism, Insulin signaling pathway, Glycolysis / Gluconeogenesis, Adipocytokine signaling pathway, Histidine metabolism, Propanoate metabolism and Retinol metabolism (Table <xref ref-type="table" rid="T5">5</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Most significantly enriched GO terms of DEGs according P value</title></caption><graphic xlink:href="oncotarget-08-61998-g002"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>The enriched GO terms of the up-regulation DEGs</title></caption></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>The enriched GO terms of thedown-regulation DEGs</title></caption></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>The enriched pathways of the up-regulation DEGs</title></caption></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>The enriched pathways of the down-regulation DEGs</title></caption></table-wrap></sec><sec id="s2_3"><title>Analysis of PPI network</title><p>Initially, to get PPI data, we uploaded 478 DEGs to STRING website. Next, the samples whose PPI score above 0.4 were selected to construct PPI networks. The PPI networks of up- and down-regulated DEGs were displayed in Figure <xref ref-type="fig" rid="F3">3</xref>. The up-regulated network was created with 182 nodes and 486 edges (Figure <xref ref-type="fig" rid="F3">3A</xref>). The proteins cyclin dependent kinase 1 (CDK1, degree = 41), cyclin B2 (CCNB2, degree = 36), and MAD2 mitotic arrest deficient-like 1 (MAD2L1, degree = 36) were hub nodes in this network. The down-regulated PPI network was constructed with 262 nodes and 633 edges (Figure <xref ref-type="fig" rid="F3">3B</xref>). The protein superoxisome proliferator activated receptor gamma (PPARG, degree = 32), acetyl-CoA carboxylase beta (ACACB, degree = 29) and catalase (CAT, degree = 27) were hub nodes in this network (Figure <xref ref-type="fig" rid="F3">3C</xref> and <xref ref-type="fig" rid="F3">3D</xref>). These genes are also enriched in Go terms and KEGG pathway excluding <italic>CAT</italic> gene.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>PPI network of DEGs obtained from the STRING database</title><p><bold>(A)</bold> PPI network of DEGs of upregulation DEGs; <bold>(B)</bold> PPI network of DEGs of downregulation DEGs; <bold>(C)</bold> Hub nodes in the PPI network constructed with upregulated genes; <bold>(D)</bold> Hub nodes in the PPI network constructed with downregulated genes.</p></caption><graphic xlink:href="oncotarget-08-61998-g003"/></fig></sec><sec id="s2_4"><title>Key genes filter and survival analysis</title><p>To visualize gene expression level of the 5 most intersecting genes: <italic>CDK1</italic>, <italic>CCNB2</italic>, <italic>MAD2L1</italic>, <italic>PPARG</italic>, and <italic>ACACB</italic>, we used pheatmap package implemented in R to generate a heatmap (Figure <xref ref-type="fig" rid="F4">4</xref>) to detect the gene expression differences between normal ductal cells and DCIS. In this step, we targeted three genes: <italic>MAD2L1</italic>, <italic>CDK1</italic> and <italic>ACACB</italic>, because they showed the most significant distinction in gene expression profile.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Heatmap of hub genes in PPI network and the corresponding enriched GO and KEGG terms</title></caption><graphic xlink:href="oncotarget-08-61998-g004"/></fig></sec><sec id="s2_5"><title>Docking the ZINC database</title><p>The 26,504 molecules of the lead-like subset of the ZINC database were docked into the structure of CDK1. The molecules were scored for receptor complementarity based on the sum of their van der Waals [using the AMBER potential] and electrostatic interaction energies [using ligand probe charges in an electrostatic potential calculated by DelPhi, corrected for ligand desolvation (Figure <xref ref-type="fig" rid="F5">5</xref>). Based on their docking scores, the compounds were ranked from best to worst fitting, and all of the compounds prioritized for experimental testing were selected from the top-ranking 500 molecules, representing 0.05% of the docked library. In addition, these molecules were inspected visually for features not captured in the docking calculation, such as chemical diversity, actual commercial availability, and an overall balance between polar and nonpolar complementarily to the binding site. Finally, 9 molecules were selected for the further study (Table <xref ref-type="table" rid="T6">6</xref>). Moreover, a structure alignment between the selected 9 compounds and the members of the DrugPort containing 1492 approved drugs were performed to find FDA approved drugs which can inhibit the activity of the CDK1. Consequently, Aminophenazone, Pomalidomide and the Rosoxacin shared large similarity to the structures of the Zinc210393, Zinc 312408 and Zinc5316172, respectively, suggesting that these compounds can bind to the active site of the CDK1 with the similar poses of the Zinc210393, Zinc 312408 and Zinc5316172 (Figure <xref ref-type="fig" rid="F6">6</xref>). It was postulated that Aminophenazone, Pomalidomide and the Rosoxacin might have therapeutic value in treating diseases derived from the dysfunction of CDK1.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>The structure of the CDK1</title><p>The active site of CDK1 identified by the FTMAP server was depicted by lime circle.</p></caption><graphic xlink:href="oncotarget-08-61998-g005"/></fig><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Top-10 docking result</title></caption></table-wrap><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>The structures of the Aminophenazone, Pomalidomide and Rosoxacin</title><p>The Aminophenazone was a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013. Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.</p></caption><graphic xlink:href="oncotarget-08-61998-g006"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>In our research, the gene expression profile information of GSE21422 was downloaded from GEO database to determine DEGs between DCIS and healthy breast tissues utilizing bioinformatics tools. Entirely, 649 DEGs including 224 up- and 425 down-regulated genes were selected. The functional enrichment analysis results revealed that up regulated genes were involved in cell cycle and Oocyte development, p53 signaling pathway, while down-regulated genes were mainly enriched in the lipid metabolism and PPAR pathway.</p><p>Moreover, Five genes were hub nodes in PPI networks. Expression profile showed that <italic>MAD2L1</italic>, <italic>CDK1</italic> and <italic>ACACB</italic>exhibit most distinctive expression pattern. These DEGs and their related functions may be involved in DCIS progression. MAD2L1, also termedas Mitotic Arrest Deficient 2-like 1, is an essential component in mitosis when chromosomes are detached to the mitotic spindle that maintains openning of chromosomes, and is involved in the spindle checkpoint during mitosis [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>]. It has great potential in assessment of prognosis and may serve as tumor biomarkers in breast cancer [<xref rid="R20" ref-type="bibr">20</xref>]. In this research, we specifically identified a subset of DCIS in which MAD2L1 plays as a biomarker. CDK1 is a member of the Ser/Thr protein kinase family [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. In this study, over-expression of CDK1 was enriched in Oocyte development and p53 signaling pathwayindicating that overexpression of CDK1 may promote DCIS progression by p53 signaling. Additionally, ACACB is a complex multifunctional enzyme system which determines the catalytic rate of fatty acid oxidation [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. However, current studies characterizing the function of ACACB in DCIS is rare. The current research revealed that the ectopic expression of ACACB reminiscent of its clinical value as a diagnostic indicator of DCIS [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. We also demonstrated that the active site of CDK1 is complementary with three FDA approved drugs Aminophenazone, Pomalidomide and the Rosoxacin, indicating novel pharmacological value beyond their antibiotic function. Although more thorough researches are warranted, anti-cancer therapeutical potency of these three drugs in breast cancer may remain to be discovered.</p><p>In conclusion, our research identified a general amount of 478 DEGs which may be associated with pathogenesis and progression of DCIS. Functional pathway enrichment analysis and PPI network construction were combined to identify three genes with significantly distinctive expression pattern and highly connecting with cancer related pathways. These genes could be a critical part in the progression of IDC and serve as prognosis indicators. Complmentarity between CDK1 and three drugs, Aminophenazone, Pomalidomide and the Rosoxacin, implies novel pharmacological value of those drugs in breast cancer.</p></sec><sec id="s4"><title>METHODS</title><sec id="s4_1"><title>Microarray data</title><p>The microarray data GSE21422 was collected from Gene Expression Omnibus(GEO) which was built upon GPL570 platform. This platform was stored by Schaefer C et al [<xref rid="R13" ref-type="bibr">13</xref>] and houses 19 microarray data of nine DCIS, 5 invasive ductal carcinoma(IDC) and 5 healthy control samples obtained from patients with breast reduction surgery.</p></sec><sec id="s4_2"><title>Data preprocessing</title><p>The original CEL data were imported into R and affy package was implemented for background correction and normalization. The expression of genes corresponding to multi probes were summarized. mas5calls in Affy was run to filter out samples with no gene expression.</p></sec><sec id="s4_3"><title>Differentially expressed genes selection</title><p>DEGs between 5 healthy samples and 9 DCIS samples were identified using Limma package [<xref rid="R14" ref-type="bibr">14</xref>]. The FDR was set to 0.01 and those genes with |log<sub>2</sub> fold change | &gt; =2 were regarded as differentially expression genes (DEGs).</p></sec><sec id="s4_4"><title>Functional annotation and pathway analysis of DEGs</title><p>Database for Annotation, Visualization, and Integrated Discovery (DAVID) is a web-server that combines functional genomic annotations with intuitive graphical summaries [<xref rid="R15" ref-type="bibr">15</xref>]. Gene lists or protein identifiers were rapidly annotated and categorized using comprehensive categorical data from Gene Ontology (GO), protein domain, and biochemical pathway membership. To investigate the inter-connection between pathways involved in pathogical mechanism of DCIS, GO and Pathway enrichment analysis on DEGs were performed with the DAVID analysis system, significance level p&lt;= 0.05.</p></sec><sec id="s4_5"><title>Protein interaction networks analysis</title><p>Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) [<xref rid="R16" ref-type="bibr">16</xref>] database (<ext-link ext-link-type="uri" xlink:href="http://string-db.org/">http://string-db.org/</ext-link>) was used to analyze protein interactions. STRING has advantages in that it aggregates most of the available information on protein-protein associations, which were benchmarked and scored against a common reference of functional partnership annotated at KEGG. There are more than 1100 organisms in extensive protein connection with global data. In this research, protein-protein interaction (PPI) network of DEGs was constructed based on STRING database where the interaction score above 0.4 was considered as <italic>de facto</italic> interaction.</p></sec><sec id="s4_6"><title>Protein preparation for docking</title><p>The structure of the CDK1 in complex with CYCLINB1 and CKS2 [PDB ID: 4YC3] was used in the docking calculations. The cofactors, ions and water molecules were removed from this complex. then the CYCLINB1 and CSK2 were also removed. The hydrogen atoms of the protein were added and optimized by the REDUCE. The active site of the CDK1 was obtained from the FTMAP server, the orientations for hydroxy groups in selected binding residues were modified to conform to the proton positions determined by the HBUILD module in CHARMM.</p></sec><sec id="s4_7"><title>Docking calculations</title><p>Virtural screening was performed to identify molecules that could bind to the active site of the CDK1. Docking of all compounds (26,504 compounds) downloaded from the lead-like subset of ZINC database was performed using DOCK 3.6 program. Complementarity of each ligand pose is scored as the sum of the receptor-ligand electrostatic and van der Waals interaction energy and corrected for ligand desolvation. Partial charges from the united-atom AMBER force field were used for all receptor atoms except for Serine, for which the dipole moment was increased as previously described to boost electrostatic scores for poses in polar contact with these important residues.</p></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare that there are no competing interests regarding the publication of this paper.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This work is supported by Medical and Health Science Research of Zhejiang (2014KYA196) and 2016 Medical Science and Technology Development Program of Yancheng City (YK2016074).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>KB</given-names></name><name name-style="western"><surname>Kuerer</surname><given-names>H</given-names></name></person-group><article-title>Ductal carcinoma in situ: treatment update and current trends</article-title><source>Curr Oncol Rep</source><year>2015</year><volume>17</volume><fpage>48</fpage><pub-id pub-id-type="pmid">26373411</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuart</surname><given-names>KE</given-names></name><name name-style="western"><surname>Houssami</surname><given-names>N</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R</given-names></name><name name-style="western"><surname>Hayen</surname><given-names>A</given-names></name><name name-style="western"><surname>Boyages</surname><given-names>J</given-names></name></person-group><article-title>Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>890</fpage><pub-id pub-id-type="pmid">26555555</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakorafas</surname><given-names>GH</given-names></name><name name-style="western"><surname>Farley</surname><given-names>DR</given-names></name><name name-style="western"><surname>Peros</surname><given-names>G</given-names></name></person-group><article-title>Recent advances and current controversies in the management of DCIS of the breast</article-title><source>Cancer Treat Rev</source><year>2008</year><volume>34</volume><fpage>483</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">18490111</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiechmann</surname><given-names>L</given-names></name><name name-style="western"><surname>Kuerer</surname><given-names>HM</given-names></name></person-group><article-title>The molecular journey from ductal carcinoma in situ to invasive breast cancer</article-title><source>Cancer</source><year>2008</year><volume>112</volume><fpage>2130</fpage><lpage>2142</lpage><pub-id pub-id-type="pmid">18383519</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Shamliyan</surname><given-names>T</given-names></name><name name-style="western"><surname>Virnig</surname><given-names>BA</given-names></name><name name-style="western"><surname>Kane</surname><given-names>R</given-names></name></person-group><article-title>Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>127</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21327465</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kretschmer</surname><given-names>C</given-names></name><name name-style="western"><surname>Sterner-Kock</surname><given-names>A</given-names></name><name name-style="western"><surname>Siedentopf</surname><given-names>F</given-names></name><name name-style="western"><surname>Schoenegg</surname><given-names>W</given-names></name><name name-style="western"><surname>Schlag</surname><given-names>PM</given-names></name><name name-style="western"><surname>Kemmner</surname><given-names>W</given-names></name></person-group><article-title>Identification of early molecular markers for breast cancer</article-title><source>Mol Cancer</source><year>2011</year><volume>10</volume><fpage>15</fpage><pub-id pub-id-type="pmid">21314937</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruneri</surname><given-names>G</given-names></name><name name-style="western"><surname>Bonizzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Vingiani</surname><given-names>A</given-names></name></person-group><article-title>Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients</article-title><source>Curr Opin Oncol</source><year>2016</year><volume>28</volume><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">27649027</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abramovitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Krie</surname><given-names>A</given-names></name><name name-style="western"><surname>Dey</surname><given-names>N</given-names></name><name name-style="western"><surname>De</surname><given-names>P</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C</given-names></name><name name-style="western"><surname>Leylandjones</surname><given-names>B</given-names></name></person-group><article-title>Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy</article-title><source>Curr Opin Oncol</source><year>2016</year><volume>28</volume><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">27606693</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>XP</given-names></name><name name-style="western"><surname>Chang</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kong</surname><given-names>XT</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function</article-title><source>Cell Rep</source><year>2014</year><volume>7</volume><fpage>180</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">24685134</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elias</surname><given-names>EV</given-names></name><name name-style="western"><surname>de Castro</surname><given-names>NP</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>PH</given-names></name><name name-style="western"><surname>Abuazar</surname><given-names>CS</given-names></name><name name-style="western"><surname>Bueno de</surname><given-names>Toledo Osorio CA</given-names></name><name name-style="western"><surname>Pinilla</surname><given-names>MG</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>SD</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>AA</given-names></name><name name-style="western"><surname>Silva</surname><given-names>WA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Napolitano e</surname><given-names>Ferriera E</given-names></name><name name-style="western"><surname>Brentani</surname><given-names>HP</given-names></name></person-group><article-title>Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>75672</fpage><lpage>75684</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12352</pub-id><pub-id pub-id-type="pmid">27708222</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menyhart</surname><given-names>O</given-names></name><name name-style="western"><surname>Harami-Papp</surname><given-names>H</given-names></name><name name-style="western"><surname>Sukumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>R</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>L</given-names></name><name name-style="western"><surname>De Barrios</surname><given-names>O</given-names></name><name name-style="western"><surname>Gyorffy</surname><given-names>B</given-names></name></person-group><article-title>Guidelines for the selection of functional assays to evaluate the hallmarks of cancer</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1866</volume><fpage>300</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">27742530</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutros</surname><given-names>PC</given-names></name></person-group><article-title>The path to routine use of genomic biomarkers in the cancer clinic</article-title><source>Genome Res</source><year>2015</year><volume>25</volume><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">26430161</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Salunga</surname><given-names>R</given-names></name><name name-style="western"><surname>Tuggle</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>J</given-names></name><name name-style="western"><surname>Enright</surname><given-names>E</given-names></name><name name-style="western"><surname>Mcquary</surname><given-names>PR</given-names></name><name name-style="western"><surname>Payette</surname><given-names>T</given-names></name><name name-style="western"><surname>Pistone</surname><given-names>M</given-names></name><name name-style="western"><surname>Stecker</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YX</given-names></name><name name-style="western"><surname>Varnholt</surname><given-names>H</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Gene expression profiles of human breast cancer progression</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>5974</fpage><lpage>5979</lpage><pub-id pub-id-type="pmid">12714683</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diboun</surname><given-names>I</given-names></name><name name-style="western"><surname>Wernisch</surname><given-names>L</given-names></name><name name-style="western"><surname>Orengo</surname><given-names>CA</given-names></name><name name-style="western"><surname>Koltzenburg</surname><given-names>M</given-names></name></person-group><article-title>Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma</article-title><source>BMC Genomics</source><year>2006</year><volume>7</volume><fpage>252</fpage><pub-id pub-id-type="pmid">17029630</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattout</surname><given-names>A</given-names></name><name name-style="western"><surname>Aaronson</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sailaja</surname><given-names>BS</given-names></name><name name-style="western"><surname>Raghu Ram</surname><given-names>EV</given-names></name><name name-style="western"><surname>Harikumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Malm</surname><given-names>J</given-names></name><name name-style="western"><surname>Sim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Nissimrafinia</surname><given-names>M</given-names></name><name name-style="western"><surname>Supper</surname><given-names>E</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PB</given-names></name><name name-style="western"><surname>Sze</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rippe</surname><given-names>K</given-names></name><etal/></person-group><article-title>Heterochromatin Protein 1beta (HP1beta) has distinct functions and distinct nuclear distribution in pluripotent versus differentiated cells</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><fpage>213</fpage><pub-id pub-id-type="pmid">26415775</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franceschini</surname><given-names>A</given-names></name><name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></name><name name-style="western"><surname>Frankild</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Simonovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Roth</surname><given-names>A</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JY</given-names></name><name name-style="western"><surname>Minguez</surname><given-names>P</given-names></name><name name-style="western"><surname>Bork</surname><given-names>P</given-names></name><name name-style="western"><surname>Mering</surname><given-names>CV</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>KJ</given-names></name></person-group><article-title>STRING v9.1: protein-protein interaction networks, with increased coverage and integration</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>D808</fpage><lpage>D815</lpage><pub-id pub-id-type="pmid">23203871</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Benezra</surname><given-names>R</given-names></name></person-group><article-title>Identification of a human mitotic checkpoint gene: hsMAD2</article-title><source>Science</source><year>1996</year><volume>274</volume><fpage>246</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">8824189</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>RM</given-names></name><name name-style="western"><surname>Meng</surname><given-names>QG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XC</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Discovery of new protein kinase CK2 inhibitors with 1,3-dioxo-2,3-dihydro-1H-indene core</article-title><source>Med Chem Comm</source><year>2016</year><volume>7</volume><fpage>1352</fpage><lpage>1355</lpage></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schibler</surname><given-names>A</given-names></name><name name-style="western"><surname>Koutelou</surname><given-names>E</given-names></name><name name-style="western"><surname>Tomida</surname><given-names>J</given-names></name><name name-style="western"><surname>Wilson-Pham</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chosed</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XB</given-names></name><name name-style="western"><surname>Wood</surname><given-names>RD</given-names></name><name name-style="western"><surname>Dent</surname><given-names>SY</given-names></name></person-group><article-title>Histone H3K4 methylation regulates deactivation of the spindle assembly checkpoint through direct binding of Mad2</article-title><source>Genes Dev</source><year>2016</year><volume>30</volume><fpage>1187</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">27198228</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>A</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HL</given-names></name><name name-style="western"><surname>Croce</surname><given-names>CM</given-names></name><name name-style="western"><surname>Grinstaff</surname><given-names>MW</given-names></name><name name-style="western"><surname>Parquette</surname><given-names>JR</given-names></name></person-group><article-title>The self-assembly of anticancer camptothecin&#8211;dipeptide nanotubes: a minimalistic and high drug loading approach to increased efficacy</article-title><source>Chemistry</source><year>2015</year><volume>21</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">25384556</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nantajit</surname><given-names>D</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M</given-names></name><name name-style="western"><surname>Duru</surname><given-names>N</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Reed</surname><given-names>JC</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name></person-group><article-title>Cyclin B1/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e12341</fpage><pub-id pub-id-type="pmid">20808790</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Su</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name></person-group><article-title>Cyclin dependent kinase 1 inhibitors: a review of recent progress</article-title><source>Curr Med Chem</source><year>2011</year><volume>18</volume><fpage>2025</fpage><lpage>2043</lpage><pub-id pub-id-type="pmid">21517772</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>S</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Araki</surname><given-names>S</given-names></name><name name-style="western"><surname>Babazono</surname><given-names>T</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>BI</given-names></name><name name-style="western"><surname>Bostrom</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>JN</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>M</given-names></name><name name-style="western"><surname>Umezono</surname><given-names>T</given-names></name><name name-style="western"><surname>Tarnow</surname><given-names>L</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T</given-names></name><name name-style="western"><surname>Gaede</surname><given-names>P</given-names></name><name name-style="western"><surname>Jorsal</surname><given-names>A</given-names></name><etal/></person-group><article-title>A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes</article-title><source>PLoS Genet</source><year>2010</year><volume>6</volume><fpage>e1000842</fpage><pub-id pub-id-type="pmid">20168990</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Pei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors</article-title><source>PeerJ</source><year>2016</year><volume>4</volume><fpage>e2140</fpage><pub-id pub-id-type="pmid">27441112</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>XK</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HP</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FL</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>QL</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>You</surname><given-names>QD</given-names></name></person-group><article-title>Synthesis and evaluation of gambogic acid derivatives as antitumor agents</article-title><source>Part III. Chem Biodivers</source><year>2013</year><volume>10</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">23341209</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>C</given-names></name></person-group><article-title>Structure and self-assembly of multicolored Naphthalene Diimides Semiconductor</article-title><source>Nano LIFE</source><year>2016</year><volume>6</volume><fpage>1642007</fpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Katsaros</surname><given-names>D</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Canuto</surname><given-names>EM</given-names></name><name name-style="western"><surname>Benedetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chu</surname><given-names>W</given-names></name><name name-style="western"><surname>Risch</surname><given-names>HA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Biological and clinical significance of MAD2L1 and BUB1, genes frequently appearing in expression signatures for breast cancer prognosis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0136246</fpage><pub-id pub-id-type="pmid">26287798</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>M</given-names></name><name name-style="western"><surname>Ozkan</surname><given-names>E</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>Structure of an intermediate conformer of the spindle checkpoint protein Mad2</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><fpage>11252</fpage><lpage>11257</lpage><pub-id pub-id-type="pmid">26305957</pub-id></element-citation></ref></ref-list></back></article>